Deciphera Pharmaceuticals Inc logo

Deciphera Pharmaceuticals Inc

FRA:D05 (USA)  
€ 23.40 (+0.86%) May 21
At Loss
P/B:
6.68
Market Cap:
€ 2.03B ($ 2.20B)
Enterprise V:
€ 1.80B ($ 1.95B)
Volume:
-
Avg Vol (2M):
91.00
Also Trade In:

Business Description

Description
Deciphera Pharmaceuticals Inc is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations function through the region of the United States.
Name Current Vs Industry Vs History
Cash-To-Debt 10.89
Equity-to-Asset 0.75
Debt-to-Equity 0.08
Debt-to-EBITDA -0.12
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 7.39
Distress
Grey
Safe
Beneish M-Score -2.35
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 59.2
9-Day RSI 71.69
14-Day RSI 73.37
6-1 Month Momentum % 18.82
12-1 Month Momentum % 2.5

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 4.19
Quick Ratio 3.94
Cash Ratio 3.27
Days Inventory 1646.8
Days Sales Outstanding 57.52
Days Payable 1441.23

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -11.8
Shareholder Yield % -0.52

Financials (Next Earnings Date:2024-08-09 Est.)

FRA:D05's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Deciphera Pharmaceuticals Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) 161.624
EPS (TTM) (€) -2.042
Beta 0.37
Volatility % 72.82
14-Day RSI 73.37
14-Day ATR (€) 0.511146
20-Day SMA (€) 20.925
12-1 Month Momentum % 2.5
52-Week Range (€) 9.512 - 23.8
Shares Outstanding (Mil) 86.48

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Deciphera Pharmaceuticals Inc Filings

Filing Date Document Date Form
No Filing Data

Deciphera Pharmaceuticals Inc Stock Events

Financials Calendars
Event Date Price(€)
No Event Data

Deciphera Pharmaceuticals Inc Frequently Asked Questions

What is Deciphera Pharmaceuticals Inc(FRA:D05)'s stock price today?
The current price of FRA:D05 is €23.40. The 52 week high of FRA:D05 is €23.80 and 52 week low is €9.51.
When is next earnings date of Deciphera Pharmaceuticals Inc(FRA:D05)?
The next earnings date of Deciphera Pharmaceuticals Inc(FRA:D05) is 2024-08-09 Est..
Does Deciphera Pharmaceuticals Inc(FRA:D05) pay dividends? If so, how much?
Deciphera Pharmaceuticals Inc(FRA:D05) does not pay dividend.

Press Release

Subject Date
No Press Release